By Liz Hoffman ( July 25, 2012, 4:05 PM EDT) -- Just two weeks after announcing its drawn-out $3 billion takeover of U.S. biotech company Human Genome Sciences Inc., British drugmaker GlaxoSmithKline PLC was hit Monday with a putative class action from Human Genome shareholders who say the price tag is too low....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.